Peter E. Boyd - 07 Mar 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
SVP, Information Technology, Human Resources and Communications
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
07 Mar 2025
Net transactions value
-$37,908
Form type
4
Filing time
11 Mar 2025, 17:47:19 UTC
Previous filing
12 Mar 2024
Next filing
08 Sep 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award $0 +80,000 +34% $0.000000 317,628 07 Mar 2025 Direct F1
transaction AQST Common Stock Tax liability $17,554 -6,624 -2.1% $2.65 311,004 07 Mar 2025 Direct F2
transaction AQST Common Stock Tax liability $20,355 -7,681 -2.5% $2.65 303,323 09 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 07 Mar 2025 Common Stock 40,000 $2.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
F3 The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Remarks:

SVP, Information Technology, Human Resources and Communications